Physician profile
Alan J Karp
NPI 1982696324
$6,087.79
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $818 · 2021: $1,468 · 2022: $1,842 · 2023: $968 · 2024: $44.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961 · Education: $52.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $960.56 |
| Education | $52.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,292.20 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $932.26 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $721.33 | 2019-2023 | Entyvio, Gattex |
| Janssen Biotech, INC. | $538.22 | 2019-2023 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $453.35 | 2019-2023 | |
| Intercept Pharmaceuticals, INC. | $337.98 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $326.54 | 2019-2023 | |
| Daiichi Sankyo INC. | $259.55 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $238.29 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $180.40 | 2022-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $129.81 | 2021-2023 | |
| Medtronic, INC. | $99.83 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $94.59 | 2022 | |
| Ironwood Pharmaceuticals, INC | $75.41 | 2020 | |
| Shire North American Group INC | $64.20 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $52.00 | 2023 | |
| Ambu INC. | $45.43 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $44.23 | 2024 | |
| Ardelyx, INC. | $38.48 | 2022 | |
| Celgene Corporation | $30.50 | 2021-2023 | Zeposia |
| Alnylam Pharmaceuticals INC. | $25.33 | 2020-2022 | |
| Amgen INC. | $24.76 | 2023 | Amjevita |
| Endogastric Solutions, INC | $20.59 | 2022-2023 | Esophyx |
| Redhill Biopharma INC. | $17.77 | 2020 | |
| Ucb, INC. | $16.34 | 2019 | |
| Genzyme Corporation | $15.13 | 2021 | |
| Alfasigma USA, INC. | $13.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Karp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.